This competitive renewal retains its specific focus on the role of histone deacetylase (HDAC) activity in cystic fibrosis (CF), building on our substantia progress in the last funding period (2010 to 2014). CF is an inherited loss-of-function disease caused principally by a Phe508 deletion in the cystic fibrosis transmembrane conductance regulator (CFTR), referred to as F508del. We are now beginning to appreciate the importance of many other mutations in providing insights into synthesis, folding, trafficking and stability/function pathways that will be addressed in this competitive renewal focused on the deacetylation ('eraser') biology of HDAC7 in correcting F508del. CFTR is a multi-membrane spanning, cAMP-regulated chloride channel. Misfolding of F508del, and likely many other mutants, reduce the synthesis, folding, trafficking and/or stability/function of CFTR resulting in the loss of cell surface conductance, premature lung failure and shortened lifespan. As such, CF is a disease of proteostasis biology as we have demonstrated under auspices of the previous funding period and in the past. Proteostasis is the cellular environment that maintains the proteome for normal cellular function. It is frequently adjusted using multiple signaling pathways to protect the cell from protein folding stress during transient insult and in response to inherite, chronic misfolding diseases. The thrust of this competitive renewal is to seek correction of CF through an understanding HDAC7 deacetylation function. During the last funding period we provided evidence that HDACs, particularly HDAC7, can exert control through multiple avenues- transcriptional, translational and/or co-/post-translational programs that are linked to different components of the proteome through acetylation/deacetylation pathways. These can operate together to achieve a level of stability and function of F508del that can be protective and corrective for CF. Herein, we propose to focus on the enabling working hypothesis that the stability and function of wild-type (WT) and F508del CFTR is strongly influenced by the HDAC7 network of deacetylation activities that operate through transcriptional, translational and/or co-/post-translational mechanisms to direct protein function, and that the HDAC7 specific network can be manipulated to provide a protective environment for CF in the clinic. To explore our working hypothesis, we propose two aims:
Aim 1 focuses on understanding the role of new targets revealed by the HDAC7 interactome generated during the last funding period that are likely responsible for HDAC7 function in correction of CF;
Aim 2 focuses on approaches to understand the role of HDAC7 in (re)balancing acetylation-deacetylation pathways involved in correcting CF variants. The combined Aims will provide systematic approach to address HDAC7 regulated pathways affecting F508del synthesis, folding, trafficking and stability/function at the cell surface. They will provide an in-depth link to the cyclical acetylation- deacetylation environments regulated by HDAC7 that may be corrective for CF disease in the clinic

Public Health Relevance

CF is an inherited loss-of-function disease caused principally by a Phe508 deletion in the cystic fibrosis transmembrane conductance regulator (CFTR) (F508del-CFTR). In this proposal we will address the role of protein acetylation-deacetylation cycles managed by histone deacetylase 7 (HDAC7) in the correction of CF. To accomplish this goal, we will focus on understanding the function of new targets revealed by the HDAC7 interactome that are likely responsible for correction, and we will use a variety of approaches to understand their specific roles in integrated pathways that affect F508del synthesis, folding, trafficking and stability/function at the cell surface that may be corrective for CF disease in the clinic.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Lung Cellular, Molecular, and Immunobiology Study Section (LCMI)
Program Officer
Smith, Robert A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Research Institute
La Jolla
United States
Zip Code
Hutt, Darren M; Loguercio, Salvatore; Roth, Daniela Martino et al. (2018) Correcting the F508del-CFTR variant by modulating eukaryotic translation initiation factor 3-mediated translation initiation. J Biol Chem 293:13477-13495
Wang, Chao; Balch, William E (2018) Bridging Genomics to Phenomics at Atomic Resolution through Variation Spatial Profiling. Cell Rep 24:2013-2028.e6
Hutt, Darren M; Mishra, Sanjay Kumar; Roth, Daniela Martino et al. (2018) Silencing of the Hsp70-specific nucleotide-exchange factor BAG3 corrects the F508del-CFTR variant by restoring autophagy. J Biol Chem 293:13682-13695
Hutt, Darren M; Loguercio, Salvatore; Campos, Alexandre Rosa et al. (2018) A Proteomic Variant Approach (ProVarA) for Personalized Medicine of Inherited and Somatic Disease. J Mol Biol 430:2951-2973
Pipalia, Nina H; Subramanian, Kanagaraj; Mao, Shu et al. (2017) Histone deacetylase inhibitors correct the cholesterol storage defect in most Niemann-Pick C1 mutant cells. J Lipid Res 58:695-708
Wang, Chao; Bouchecareilh, Marion; Balch, William E (2017) Measuring the Effect of Histone Deacetylase Inhibitors (HDACi) on the Secretion and Activity of Alpha-1 Antitrypsin. Methods Mol Biol 1639:185-193
Veit, Gudio; Avramescu, Radu G; Chiang, Annette N et al. (2016) From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell 27:424-33
Amaral, Margarida D; Balch, William E (2015) Hallmarks of therapeutic management of the cystic fibrosis functional landscape. J Cyst Fibros 14:687-99
Rauniyar, Navin; Subramanian, Kanagaraj; Lavallée-Adam, Mathieu et al. (2015) Quantitative Proteomics of Human Fibroblasts with I1061T Mutation in Niemann-Pick C1 (NPC1) Protein Provides Insights into the Disease Pathogenesis. Mol Cell Proteomics 14:1734-49
Pankow, Sandra; Bamberger, Casimir; Calzolari, Diego et al. (2015) ?F508 CFTR interactome remodelling promotes rescue of cystic fibrosis. Nature 528:510-6

Showing the most recent 10 out of 37 publications